Press Releases
Boehringer Ingelheim launches EURICAN® L4 vaccine, offering outstanding protection against leptospirosis in dogs
Boehringer Ingelheim launches VETMEDIN® Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs
Focus on Health Equity drives upgrade in Access to Medicine Index Ranking
Newsbits
Boehringer Advances Oncology Research
European Commission approves SPEVIGO® for new and expanded indications in generalized pustular psoriasis
Boehringer Ingelheim invests in precision cancer treatments
Stories
Their dogs are their world
Building blocks of our future
Rabies? Not in Mexico!
Media Contacts
Head of Global Media Relations
E-Mail:
harro.ten_wolde@boehringer-ingelheim.com
Phone Number:
+49 (6132) 77-181352
Senior Media Relations Manager
E-Mail:
tereza.urbankova@boehringer-ingelheim.com
Phone Number:
+49 (6132) 77-184817
Senior Media Relations Manager
E-Mail:
mark_william.valentiner@boehringer-ingelheim.com
Tel.: +49 (6132) 77-170136
Media Relations Manager
E-Mail:
valerie-chiara.nestle@boehringer-ingelheim.com
Phone Number:
+49 (7351) 54-175075
Head of Human Pharma Communications
E-Mail:
anthonia.aboyeji@boehringer-ingelheim.com
Phone Number:
+49 (6132) 77-172370
Head of Animal Health Communications
E-Mail:
Heidi.DeWit-Sommerfeld@boehringer-ingelheim.com
Phone Number:
+49 (6132) 77-171799
Head of Innovation Unit Communications
E-Mail: camilla.krogh_lauritzen@boehringer-ingelheim.com
Phone Number: +45 2272 4806
Current Events
Past Events
Annual Results Press Conference 2023
